Dermatology Times February 2025 Recap

Clearances, Approvals, Updates, and Recommendations

Rezpegaldesleukin Receives Fast Track Designation for Moderate to Severe AD

Nektar Therapeutics’ investigational biologic targets the IL-2 receptor complex.

FDA Accepts sBLA for Dupilumab as Potential BP Treatment

Patients treated with dupilumab showed significant reductions in disease severity, itch, and corticosteroid use.

FDA Clears Zabalafin Hydrogel’s Investigational New Drug Application for AD

Alphyn’s therapy uniquely treats both the immune system and bacterial components of atopic dermatitis.

Ustekinumab Biosimilar Yestintek Launches in the US, Expanding Treatment Access for Chronic Autoimmune Diseases

Ustekinumab-kfce is available for the treatment of chronic autoimmune conditions like Crohn’s disease, ulcerative colitis, and plaque psoriasis.

FDA Accepts Supplemental New Drug Application for Arcutis’ Roflumilast in Children with AD

A PDUFA target action date has been set for October 13, 2025.

Big Studies and Big Data

Topical TCA and Methoxsalen Not Clinically Effective for Acral Vitiligo
Each treatment saw very mild clinical and dermatologic responses with low levels of patient satisfaction.

Post-Hoc Analysis of ALLEGRO-2b/3 Trial Highlights Patient-Reported Outcome Improvements

Clinicians observed a positive relationship between scalp hair regrowth and downstream treatment benefits for patients with alopecia areata.

New Study Examines Connection Between Formulation and Benzene Levels in BPO Products

Barbieri et al evaluated product use, benzoyl peroxide concentration, days until expiration, and more.

New Data on Bimekizumab’s Long-term HS Efficacy

Bimekizumab demonstrated long-term effectiveness in patients with HS, with over 85% maintaining response and reduced draining tunnels.

5-Year Study Backs Deucravacitinib’s Safety and Efficacy

The POETYK PSO LTE trial found deucravacitinib effective in sustaining PASI 75 and PASI 90 responses.

Ritlecitinib Generally Well-Tolerated in Pediatric Patients with Alopecia, According to Phase 1 Study

Patients aged 6 to 12 had little to no adverse events and no pharmacokinetic abnormalities were noted.

DELTA TEEN Highlights Potential of Delgocitinib in Adolescents With Chronic Hand Eczema

The phase 3 clinical trial investigating delgocitinib cream for adolescents with moderate to severe CHE met its primary and key secondary endpoints.

Dermatological Impact of Martian Space Travel

Geological particles can cause skin irritation, allergies, and long-term dermatological conditions.

SLIDESHOW: Exploring Merz Aesthetics' Global Confidence Study Data

Merz Aesthetics' global study highlights how aesthetic treatments boost self-confidence, well-being, and empower individuals, transforming self-care practices.

Market and Pharma News, Drug Watch

VYNE Therapeutics Advances VYN202 with Phase 1b Trial in Moderate to Severe Plaque Psoriasis

VYNE has initiated a phase 1b trial for its oral BD2-selective BET inhibitor.
Allergan Medical Institute to Launch 3 New US Training Centers for Clinicians

The state-of-the-art facilities in California, Georgia, and Texas will expand AMI’s curriculum to providers of all levels.

Patrick Burnett, MD, PhD, Highlights Arcutis’ New Seborrheic Dermatitis Initiative With Odell Beckham Jr.

The overwhelmingly positive feedback from both clinicians and patients reinforces the unmet need roflumilast foam is addressing in seborrheic dermatitis care.
How PathAI’s PathAssist Derm Tool Aims to Enhance Skin Cancer Diagnosis and Workflow Efficiency

Although the tool is currently designed for research use only, CEO Andy Beck, MD, PhD, is excited about its future in clinical dermatopathology.

Expert Panel Endorses Image-Guided Superficial Radiation Therapy as a Safe and Effective Treatment for Nonmelanoma Skin Cancer

A dermatology expert panel confirms IGSRT as a safe, effective first-line treatment for select nonmelanoma skin cancer cases.

How the LIMITLESS Initiative Supports Female Leaders in Dermatology

Mindy Haws, MD, spoke to Dermatology Times about the new videos, podcasts, and other resources LIMITLESS offers for women at all stages of their careers.

Strides for Skin Health Equity

Should “Advanced Practice Provider” Represent Both PAs and NPs?

Uniting all professions should be the goal as it concerns the patient and the access to care.

Bridging Dermatology and Psychological Support

A global review found that skin condition advocacy groups offer diverse mental health resources, but accessibility gaps persist worldwide.

Sunscreen Use Among Cyclists Falls Short

A recent study found sunscreen use is higher among women but often not reapplied properly.

Nail Diseases in Skin of Color: A Research Gap

This study highlights the urgent need for improved awareness, diagnosis, and treatment of inflammatory nail diseases in patients with skin of color.

Sunscreen is the Best Way to Prevent Post-Inflammatory Hyperpigmentation in Skin of Color

Although more research is needed to fill this gap, sunscreen had the greatest success rates of all the prevention methods in this literature review.

Don’t miss a moment of Dermatology Times by signing up for our eNewsletters and subscribing to receive the free print issue and supplements each month.